Abivax S.A. Files 2024 Annual Report

Ticker: AAVXF · Form: 20-F · Filed: Mar 24, 2025 · CIK: 1956827

Abivax S.A. 20-F Filing Summary
FieldDetail
CompanyAbivax S.A. (AAVXF)
Form Type20-F
Filed DateMar 24, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: annual-report, 20-F, pharmaceuticals

Related Tickers: ABVX

TL;DR

Abivax dropped its 2024 20-F. Check financials.

AI Summary

Abivax S.A. filed its 20-F for the fiscal year ending December 31, 2024. The company, based in Paris, France, operates in the pharmaceutical preparations sector. Key financial data and operational details for 2024 are presented in this annual report.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of Abivax's financial performance and business operations for the past fiscal year, crucial for investment decisions.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Abivax faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

  • 2024 — Fiscal Year End (The period covered by the annual report.)
  • 2025-03-24 — Filing Date (The date Abivax submitted its 20-F to the SEC.)

Key Players & Entities

  • Abivax S.A. (company) — Filer of the 20-F
  • Paris, France (location) — Company's business address
  • 2024-12-31 (date) — Fiscal year end
  • 2025-03-24 (date) — Filing date

FAQ

What is the primary business of Abivax S.A. as indicated in the filing?

Abivax S.A. is primarily involved in the Pharmaceutical Preparations industry, with the SIC code 2834.

What is the fiscal year end for Abivax S.A. reported in this 20-F?

The fiscal year end for Abivax S.A. is December 31, 2024.

On what date was this 20-F filing submitted to the SEC?

This 20-F filing was submitted to the SEC on March 24, 2025.

Where is Abivax S.A. located?

Abivax S.A. is located in Paris, France, with its business address at 7 BD HAUSSMANN, 75009.

What stock exchange is Abivax S.A. listed on, as suggested by the filing?

The filing mentions 'abvx:AmericanDepositorySharesNASDAQGlobalMarketMember' and 'abvx:OrdinarySharesNASDAQGlobalMarketMember', indicating a listing on the NASDAQ Global Market.

Filing Details

This Form 20-F (Form 20-F) was filed with the SEC on March 24, 2025 regarding Abivax S.A. (AAVXF).

View full filing on EDGAR

View Full Filing

View this 20-F filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.